Learn more about BRENZAVVY for patients.

Brenzavvy (bexagliflozin) SGLT2 Inhibitor for Type 2 Diabetes

What can BRENZAVVY do for Patients with Type 2 Diabetes?

Empower yourself in managing your Type 2 Diabetes with an affordable and budget-friendly solution. Meet BRENZAVVY (bexagliflozin), now accessible at independent pharmacies nationwide. BRENZAVVY is the first FDA-approved, once-daily SGLT-2 inhibitor designed to lower blood sugar levels in adults with type 2 diabetes. BRENZAVVY is priced at less than $50 per month, equating to just $1.56 per day.

BRENZAVVY’s (bexagliflozin) safety and effectiveness have undergone assessment in 23 clinical studies, involving over 5,000 adult participants.

BRENZAVVY (bexagliflozin) has been clinically proven to reduce A1c

Multiple Phase 2 and Phase 3 studies have shown that BRENZAVVY significantly reduces hemoglobin A1c and fasting blood sugar in adults with type 2 diabetes.

MAY REDUCE BLOOD PRESSURE

While BRENZAVVY has not obtained FDA approval specifically for reducing blood pressure, clinical studies involving adults with type 2 diabetes revealed consistent and lasting decreases in blood pressure. The observed reduction remained significant over a period of up to 96 weeks of treatment with BRENZAVVY 20 mg compared to a placebo.

MAY SUPPORT WEIGHT LOSS

While BRENZAVVY has not been granted FDA approval specifically for weight loss, clinical studies have noted modest decreases in weight. Adults with type 2 diabetes experienced an average reduction in body weight ranging from 4 to 8 pounds after 24 weeks of treatment with BRENZAVVY 20 mg, whereas participants in the same studies who received a placebo demonstrated an average reduction in body weight of up to 3 pounds.

Explore the Comprehensive Details of BRENZAVVY

Click to download the BRENZAVVY Medication Guide.

Learn More at BRENZAVVY.com